peginterferon beta-1a

Home
Ligands
peginterferon beta-1a

GtoPdb Ligand ID: 7637

Synonyms: interferon beta 1-alpha | PEG-INF-β-1a | Plegridy®

peginterferon beta-1a is an approved drug (EMA and FDA (2014))

Compound class: Peptide or derivative

Comment: This drug is a PEGylated version of recombinant human interferon beta-1a [1].

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

References
1. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM et al.. (2006) N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem, 17 (1): 179-88. [PMID:16417267]
2. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S et al.. (2014) Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol, 13 (7): 657-65. [PMID:24794721]

References

1. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM et al.. (2006)
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Bioconjug Chem, 17 (1): 179-88. [PMID:16417267]

2. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S et al.. (2014)
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Lancet Neurol, 13 (7): 657-65. [PMID:24794721]